FBRX
Forte Biosciences Inc
NASDAQ: FBRX · HEALTHCARE · BIOTECHNOLOGY
$28.03
+6.23% today
Updated 2026-04-29
Market cap
$537.90M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-4.71
Dividend yield
—
52W range
$6 – $36
Volume
0.3M
Forte Biosciences Inc (FBRX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-21.04M | $-29.54M | $-31.13M | $-34.47M | $-2.77M | $-18.42M | $-16.68M | $-8.19M | $-28.71M | $-30.75M | $-50.88M |
| Capital expenditures | $231000.00 | $525000.00 | $655000.00 | $1.97M | $162000.00 | $0.00 | $61000.00 | $0.00 | $88000.00 | $37000.00 | $116000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | — | $4.45M | $6.87M | $35710.00 | $956000.00 | $4.21M | $4.01M | $3.28M | $3.10M | $6.26M |
| Free cash flow | $-21.27M | $-30.06M | $-31.79M | $-36.44M | $-2.93M | $-18.42M | $-16.74M | $-8.19M | $-28.79M | $-30.78M | $-51.00M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — | — |